Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Appili Therapeutics has received the final court approval for its acquisition by Aditxt, Inc., marking a significant milestone in the transaction process. This move will eventually lead to Appili’s delisting from the Toronto Stock Exchange. The transaction is expected to close by the end of 2024, subject to remaining conditions.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.